Victor Yu

Victor Yu

Auto-generated profile, based on publicly available information

Victor Yu

Yale Univ, Sch Med, Dept Anesthesiol & Pain Med, New Haven, CT USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
DGDiana C. Gomez-Manjarres
Diana C. Gomez-Manjarres
DADierdre B. Axell-House
Dierdre B. Axell-House
DPDivya C. Patel
Divya C. Patel
JOJohn Odackal
John Odackal
VYVictor Yu
Victor Yu
BMBorna Mehrad
Borna Mehrad
BACKGROUND: Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis that short-term treatment with sirolimus reduces the concentration of CXCR4 + circulating fibrocytes in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a short-term randomized double-blind placebo-controlled crossover pilot trial to assess the safety and tolerability of sirolimus in IPF. Participants were randomly assigned to sirolimus or placebo for approximately 6 weeks, and after a 4-week washout, they were assigned to the alternate treatment. Toxicity, lung function, and the concentration of circulating fibrocytes were measured before and after each treatment. RESULTS: In the 28 study participants, sirolimus resulted in a statistically significant 35% decline in the concentration of total fibrocytes, 34% decline in CXCR4 + fibrocytes, and 42% decline in fibrocytes expressing α-smooth muscle actin, but no significant change in these populations occurred on placebo. Respiratory adverse events occurred more frequently during treatment with placebo than sirolimus; the incidence of adverse events and drug tolerability did not otherwise differ during therapy with drug and placebo. Lung function was unaffected by either treatment, with the exception of a small decline in gas transfer during treatment with placebo. CONCLUSION: As compared with placebo, short-term treatment with sirolimus resulted in reduction of circulating fibrocyte concentrations in participants with IPF, with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov, accession no. NCT01462006. FUNDING: NIH R01HL098329 and American Heart Association 18TPA34170486.

16 May 2000 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
NSNina Singh
Nina Singh
VYVictor L. Yu
Victor L. Yu

18 October 2023 in Journal of PeriAnesthesia Nursing
Verified
Journal Article
Closed access
DHDaniel Haddad
Daniel Haddad
VYVictor Yu
Victor Yu
RCRobert Chow
Robert Chow
DYDavid Yanez
David Yanez
KRKanishka Rajput
Kanishka Rajput